[1]刘光华,俞炬明,范国平,等.肝细胞癌患者伴发糖尿病行肝动脉化疗栓塞术的预后因素分析 [J].介入放射学杂志,2017,(10):926-930.
 LIU Guanghua,YU Juming,FAN Guoping,et al.Analysis of prognostic factors in patients with hepatocellular carcinoma complicated by diabetes mellitus after transcatheter arterial chemoembolization[J].journal interventional radiology,2017,(10):926-930.
点击复制

肝细胞癌患者伴发糖尿病行肝动脉化疗栓塞术的预后因素分析



()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2017年10期
页码:
926-930
栏目:
临床研究
出版日期:
2017-10-25

文章信息/Info

Title:
Analysis of prognostic factors in patients with hepatocellular carcinoma complicated by diabetes mellitus after transcatheter arterial chemoembolization
作者:
刘光华 俞炬明 范国平 董国芳 王瑞芝 汪登斌 欧阳强
Author(s):
LIU Guanghua YU Juming FAN Guoping DONG Guofang WANG Ruizhi WANG Dengbin OUYANG Qiang
Department of Interventional Radiology, Affiliated Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200092, China
关键词:
【关键词】 肝细胞癌 肝动脉栓塞化疗 糖尿病 预后
文献标志码:
A
摘要:
【摘要】 目的 分析糖尿病(DM)对不可切除肝细胞癌(HCC)患者TACE术后预后的影响。方法 选取2010年1月-2015年6月就诊于上海交通大学医学院附属新华医院行TACE术的HCC患者 858例,其中合并 DM患者175例(DM组),HCC未合并 DM患者683例(非DM组),分析两组患者一般临床资料及总体生存的差异。生存率用Kaplan- Meier法计算,组间差异采用Log- Rank方法,采用 Cox比例风险回归分析不可切除 HCC患者TACE术预后的影响因素。结果 两组性别、年龄、血清总胆红素、白蛋白、凝血酶原时间、甲胎蛋白(AFP)、Child- Pugh分级、肿瘤最大直径和数目、肝硬化、TACE治疗次数以及BCLC分期比较,差异均无统计学意义(P>0.05);DM组空腹血糖(FPG)水平高于非DM组(P<0.05)。DM组患者 1、3、5年生存率为 60.9%、27.5%和10.7%,非DM组为 70.9%、36.0%和17.6%,经 Log- rank检验,差异存在统计学意义(P=0.008)。将上述变量进行多因素 Cox比例风险回归分析结果显示,肿瘤最大直径>5 cm、肿瘤数目多发、AFP>20 ng/ml、BCLC分期、以及合并DM是影响 HCC患者 TACE预后的独立危险因素。结论 DM是影响不可切除HCC患者 TACE后独立危险因素。

参考文献/References:

[1] Davila JA, Morgan RO, Shaib Y, et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study[J]. Gut, 2005, 54: 533- 539.
[2] Lai SW, Chen PC, Liao KF, et al. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti- diabetic therapy: a population- based cohort study[J]. Am J Gastroenterol, 2012, 107: 46- 52.
[3] Koh WP, Wang R, Jin A, et al. Diabetes mellitus and risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study[J]. Br J Cancer, 2013, 108: 1182- 1188.
[4] Li Q, Wang Y, Ma T, et al. Clinical outcomes of patients with and without diabetes mellitus after hepatectomy: a systematic review and meta- analysis[J]. PLoS One, 2017, 12: e0171129.
[5] Zhang J, Gong F, Li L, et al. Diabetes mellitus and the neutrophil to lymphocyte ratio predict overall survival in non- viral hepatocellular Carcinoma treated with transarterial chemoembolization[J]. Oncol Lett, 2014, 7: 1704- 1710.
[6] 黄高峰, 庞志刚, 贾华磊. 糖尿病对巴塞罗那临床肝癌分期B期原发性肝细胞癌患者经肝动脉化疗栓塞术后预后的影响研究[J]. 中国全科医学, 2016, 19: 2010- 2014.
[7] Bruix J, Sherman M. Management of hepatocellular carcinoma[J]. Hepatology, 2005, 42: 1208- 1236.
[8] American Diabetes Association. Classification and diagnosis of diabetes[J]. Diabetes Care, 2017, 40(Suppl 1): S11- S24.
[9] 敖 劲, 张跃伟, 徐 克. 明胶海绵微粒经动脉栓塞治疗原发性肝癌的研究现状[J]. 介入放射学杂志, 2011, 20: 1010- 1013.
[10] Wada H, Eguchi H, Noda T, et al. Selection criteria for hepatic resection in intermediate- stage(BCLC stage B) multiple hepato- cellular carcinoma[J]. Surgery, 2016, 160: 1227- 1235.
[11] Ciria R, Lopez- Cillero P, Gallardo AB, et al. Optimizing the management of patients with BCLC stage- B hepatocellular carcinoma: modern surgical resection as a feasible alternative to transarterial chemoemolization[J]. Eur J Surg Oncol, 2015, 41: 1153- 1161.
[12] Wang C, Wang X, Gong G, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta- analysis of cohort studies[J]. Int J Cancer, 2012, 130: 1639- 1648.
[13] Liu H, Ma Q, Li J. High glucose promotes cell proliferation and enhances GDNF and RET expression in pancreatic cancer cells[J]. Mol Cell Biochem, 2011, 347: 95- 101.
[14] Hosokawa T, Kurosaki M, Tsuchiya K, et al. Hyperglycemia is a significant prognostic factor of hepatocellular carcinoma after curative therapy[J]. World J Gastroenterol, 2013, 19: 249- 257.
[15] Wang YY, Huang S, Zhong JH, et al. Impact of diabetes mellitus on the prognosis of patients with hepatocellular carcinoma after curative hepatectomy[J]. PLoS One, 2014, 9: e113858.
[16] 常中飞, 段 峰, 孙红梅, 等. 肝动脉化疗栓塞治疗原发性肝癌合并糖尿病的预后因素分析[J]. 中华介入放射学电子杂志, 2015, 3: 13- 17.

相似文献/References:

[1]姚雪松,李 槐.不可手术切除的肝细胞癌的疗效评价标准——改良RECIST标准更可靠[J].介入放射学杂志,2012,(03):177.
 . Therapeutic evaluation criterion of inoperable hepatocellular carcinomas: modified RECIST as a more reliable standard[J].journal interventional radiology,2012,(10):177.
[2]徐增斌,彭志毅,章熙道,等.小肝癌DSA诊断作介入治疗[J].介入放射学杂志,1996,(01):45.
[3]梁茂全,苏洪英. 肝癌化疗栓塞前后甲胎蛋白变化模式的临床意义[J].介入放射学杂志,2012,(04):333.
 .The transformation pattern of serum аfetoprotein after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma: its clinical significance [J].journal interventional radiology,2012,(10):333.
[4]孙 磊,施海彬,刘 圣,等.肝细胞癌肝动脉门静脉分流形成的相关因素分析[J].介入放射学杂志,2012,(03):206.
 ,,et al.The factors related to the formation of arterioportal shunting in patients with hepatocellular carcinomas [J].journal interventional radiology,2012,(10):206.
[5]沈海洋,刘瑞宝,刘 岩,等. 肝右叶前、后段原发性肝癌TACE后VEGF及CD34的表达水平 ;[J].介入放射学杂志,2012,(06):469.
 SHEN Hai- yang,LIU Rui- bao,LIU Yan,et al. The expression levels of vascular endothelial growth factor and CD34 in residual cancerous tissues of primary hepatocellular carcinoma located at anterior and posterior segments of right lobe liver after TACE[J].journal interventional radiology,2012,(10):469.
[6]李晓峰,钱国军,张 磊,等. 微波高功率条件下消融原发性肝癌的初步研究[J].介入放射学杂志,2011,(12):974.
 LI Xiao-feng,QIAN Guo-jun,ZHANG Lei,et al.Microwave ablation with high output power for the treatment of hepatocellular carcinoma: a preliminary study[J].journal interventional radiology,2011,(10):974.
[7]彭辽河,胡晓燕,李 杰,等. 18F-FDG PET/CT显像在肝细胞癌TACE术后残留或复发病灶检出中的应用价值[J].介入放射学杂志,2012,(08):636.
 PENG Liao- he,HU Xiao- yan,LI Jie,et al. Clinical application of 18F- FDG PET/CT imaging in detecting residual lesions or recurrence foci of hepatocellular carcinoma after TACE treatment[J].journal interventional radiology,2012,(10):636.
[8]罗中华,秦 勉,张学昕,等.原发性肝癌合并下腔静脉及右心房癌栓的动脉内化疗栓塞治疗[J].介入放射学杂志,2012,(12):1035.
 LUO Zhong? hua,QIN Mian,ZHANG Xue? xin,et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma complicated by tumor thrombus in inferior vena cava and right atrium[J].journal interventional radiology,2012,(10):1035.
[9]陆小华,朱小庆,茅国新.肝细胞癌相关单核苷酸多态性的研究进展[J].介入放射学杂志,2013,(06):520.
 LU Xiao? hua,ZHU Xiao? qing,MAO Guo? xin.. Hepatocellular carcinoma?蛳 related single nucleotide polymorphisms: recent advances in research[J].journal interventional radiology,2013,(10):520.
[10]姚雪松,闫 东,曾辉英,等.TACE联合索拉非尼治疗不能手术切除肝细胞癌介入治疗间隔时间的分析[J].介入放射学杂志,2014,(09):769.
 YAO Xue song,YAN Dong,ZENG Hui ying,et al.TACE combined with sorafenib for inoperable hepatocellular carcinoma: analysis of treatment interval[J].journal interventional radiology,2014,(10):769.
[11]王晓维,付守忠,戴 锋,等.肝动脉栓塞化疗联合射频消融与联合微波消融治疗原发性肝癌的疗效和安全性比较 [J].介入放射学杂志,2016,(08):673.
 WANG Xiao-wei,FU Shou-zhong,DAI Feng,et al.The curative effect and safety in treating primary hepatocellular carcinoma: comparison between TACE plus radiofrequency ablation and TACE plus microwave ablation [J].journal interventional radiology,2016,(10):673.

备注/Memo

备注/Memo:
(收稿日期:2017-04-06)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2017-10-15